SITE010-0294

completed

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE010 (ESP) · Dr. Silva
consented 2023-02-15

AEs

Serious

Dropout signal

–

Adverse events

severe serious assessed

Grade 4 Decreased appetite — outcome: RECOVERED/RESOLVED; onset 2023-04-21 (study day 53); relationship: N; serious criteria: life-threatening

mild assessed

Grade 1 Fatigue — outcome: RECOVERED/RESOLVED; onset 2023-05-25 (study day 87); relationship: N

mild assessed

Grade 1 Asthenia — outcome: RECOVERED/RESOLVED; onset 2023-05-29 (study day 91); relationship: not assessed

moderate assessed

Grade 2 Dyspnoea — outcome: RECOVERED/RESOLVED; onset 2023-06-09 (study day 102); relationship: not assessed

moderate assessed

Grade 2 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2023-06-23 (study day 116); relationship: Y

moderate assessed

Grade 2 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-06-26 (study day 119); relationship: N

mild assessed

Grade 1 Anaemia — outcome: RECOVERED/RESOLVED; onset 2023-06-29 (study day 122); relationship: not assessed

Data queries

No data queries.